Caroline Sigman, President, CEOA regulatory service provider, CCS Associates, offers services to guarantee the efficiency of the drug development process. It provides a wide range of services, including technical and support services for clinical research, preclinical study design strategies, chemical information sciences, and R&D support. The firm has made significant contributions to bioinformatics, created master databases of chemical data, and collaborated with clients in the public and private sectors to use nonclinical and clinical data to develop pharmaceuticals.
Before becoming a regulatory contractor, CCSA wrote dossiers and chemical and drug evaluation documents for a small group of specialists at the National Cancer Institute (NCI). After establishing itself as an R&D service company, it developed a drug development regulatory program along with NCI, and since 1995, has continued to be in the NCI regulatory service sector for cancer prevention.
“As part of a consortium foundation comprised of government and pharmaceutical representatives, CCSA has worked with the government, specifically the FDA and the NIH, to develop standards for testing protocols,” says Caroline Sigman, President and CEO of CCSA.
The proliferation of new technologies in clinical research, particularly genomic profiling, has led to an influx of data. Due to this, isolating data relevant to product development has become increasingly challenging. Data analysis services provided by CCSA are specifically designed to effectively address data sorting and further drug development. Providing consultation on drug development strategies is a critical component of CCSA’s regulatory services. In collaborative programs with the National Heart, Lung, and Blood Institute (NHLBI), neurosciences groups at NIH, and the National Center for Advancing Translational Science (NCATS), it helped conceive decision plans for drug development. CCSA also helps clients implement technology that aligns with modern standards for clinical trials, like biomarkers based on AI. An active member of various national and industry-level committees, CCSA works to improve the current standards of assay testing.
A leading provider of drug regulatory services, CCS Associates aims to efficiently guide clients through the drug development process. Through standardized regulatory resources, it provides clients with additional assistance to manage, process, and report clinical research data. Clients with less expertise in the pharmaceutical industry benefit from CCSA’s gap analysis, which determines the available data, the kinds of efficacy and toxicity tests needed, and toxicity levels permitted for clinical trials. The firm also assists clients with obtaining FDA approval for investigational new drugs (INDs) by creating and submitting the relevant documentation to regulatory bodies as part of its marketing application services.
As part of a consortium foundation comprised of government and pharmaceutical representatives, CCSA has worked with the government, specifically the FDA and the NIH, to develop standards for testing protocols
CCSA’s regulatory services are designed to complement the entire R&D process from start to finish. The regulatory service company is committed to serving the life science research sector with unrivaled scientific and strategic support to facilitate the commercialization of diagnostic, preventative, and therapeutic medical products for the benefit of humanity.
Choosing a Regulatory Partner for Complex Clinical Development
Regulatory consulting in healthcare has changed over the last few years. It is no longer enough for a firm to prepare filings at scheduled milestones and keep programs administratively on track. Today’s development environment moves too quickly for that. Clinical programs now involve adaptive trial models, emerging data expectations, novel mechanisms and far more interaction with regulators earlier in development. That has raised the bar for what sponsors should expect from a regulatory partner.
For executives evaluating providers, the real question is not whether a firm can submit documents. It is whether the team can help shape smarter development decisions before regulatory issues become expensive delays. Weak partners tend to operate downstream, reacting to problems once they surface. Stronger firms work much closer to the science, helping companies think through evidence strategy, protocol design, agency positioning and long-term submission planning from the beginning.
That distinction matters most in complex programs. Platform trials, umbrella studies, master protocols and government-supported development pathways create layers of operational and regulatory interdependence that traditional consulting models are not always built to manage. A single regulatory decision can affect study comparability, site readiness, safety oversight and even future expansion options for the program itself. In these settings, sponsors need advisors who understand how to preserve scientific consistency while keeping the regulatory path practical and defensible.
FDA interaction has also become more continuous and more consequential. Earlier engagement can reduce uncertainty, but only if sponsors enter those meetings with a disciplined strategy. Companies need to ask precise questions, frame evidence gaps carefully and avoid creating commitments that later limit development flexibility. Experienced regulatory teams play an important role here because they connect scientific rationale, clinical planning and submission timing into a coherent regulatory story rather than treating agency meetings as isolated events.
Another area executives often underestimate is continuity. Regulatory work does not happen in silos. Writing quality, safety documentation, eCTD readiness and cross-functional coordination all influence how clearly a development program is understood by reviewers. Providers that stay involved across multiple stages of development usually create far less rework later, particularly when early-stage assets begin transitioning toward pivotal or commercial planning.
CCS Associates is particularly well positioned for organizations that need science-driven regulatory support rather than basic submission management. The firm supports INDs, NDAs, ANDAs, IDEs, DMFs, CTAs, orphan drug designations and pre-IND meeting packages in eCTD format, but its value extends beyond documentation. Its experience includes work with master protocols, master IND structures, I-SPY 2, Lung-MAP, government-backed development programs and sponsors advancing from early clinical research into pivotal-stage development. For healthcare executives managing complex drug, biologic or device programs, CCS Associates stands out as a strong Gold Standard choice because of its combination of regulatory depth, scientific understanding and long-term program involvement.
...Read more
